Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00133471
Status:
COMPLETED
Last Update Posted:
2010-08-27
First Post:
2005-08-19
Brief Title:
Inactivated Influenza AH9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
Evaluation of the Reactogenicity and Immunogenicity of Four Dosage Levels of Intramuscular Monovalent Inactivated Influenza AH9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults
Status:
COMPLETED
Status Verified Date:
2009-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the bodys reactions and immune responses after receiving different strengths of a H9N2 influenza virus vaccine with and without an adjuvant given into the arm muscle Study participants will include up to 96 healthy adults ages 18-34 The 4 dosages of the experimental H9N2 vaccine to be tested in this study are the following 375 75 15 and 30-mcg with and without MF59 adjuvant Participants will be vaccinated on Days 0 and 28 Participants will record any vaccine side effects in a diary for 7 days following each vaccination Participants will return to the clinic on days 2 and 7 after vaccination Blood samples will be collected 7 days following each vaccination Serum and nasal wash specimens will be collected before each vaccination and 4 weeks after injections 0 4 and 8 weeks Participants will be involved in study related procedures for up to 8 months
Detailed Description:
The primary goal of this study is to assess the safety of 4 different dosages of purified monovalent surface antigen SA influenza AH9N2 virus vaccine with or without MF59 adjuvant and administered intramuscularly to ambulatory adults The hypothesis is that all dosage levels of adjuvanted and nonadjuvanted vaccine will be well tolerated The primary objective of this project is to evaluate the safety of 4 dosage levels of monovalent surface antigen SA influenza AH9N2 virus vaccine given with or without MF59 adjuvant The primary endpoint is the frequency and severity of solicited local and systemic adverse events in each vaccine dosage level group The secondary objective of this project is to determine the immunogenicity of 4 dosage levels of monovalent surface antigen SA influenza AH9N2 virus vaccine given with or without MF59 adjuvant The secondary endpoints include the following the proportions of subjects in each vaccine dosage group that achieve a serum HAI titer of at least 132 one month after the second vaccination the geometric mean titer GMT of serum HAI antibody against the influenza AH9N2 virus one month after the second vaccination the rates of significant increases in titer between pre- and post-immunization serum samples defined as seroconversion-ie increase in titer from 14 pre-immunization to at least 18 after vaccination or 4-fold or greater increase in titer between pre- and post-immunization samples 28 days after each vaccination days 28 and 56 and the proportion of subjects with a 4-fold or greater increase in percent HA-specific antibody in nasal wash specimens for each vaccine group The study will be a double-blind evaluation of 4 dosage levels of study vaccine The 4 dosage levels to be tested are 375- 75- 15- and 30-mcg of HA of the vaccine strain with and without MF59 adjuvant Because all dosage levels are lower than the total hemagglutinin content of the FLUAD vaccine used in Europe subjects will be enrolled into all dosage and adjuvant groups concurrently using a randomized double-blind study design Ninety-six persons 18-34 years of age will be enrolled A single lot of monovalent inactivated SA influenza AH9N2 vaccine will be used throughout the trial All injections will be administered in a 05-mL volume into the deltoid muscle Screening and safety laboratory examinations will be assessed before the first dose and 7 days after each vaccination Assessments for reactogenicity will be done for at least 20 minutes after each vaccination in the clinic 2 and 7 days after each inoculation via diary card for seven days after each vaccination and via phone or other contact at 7 months after the first vaccination for any serious adverse events during the entire study period Serum and nasal wash samples collected on days 0 28 and 56 will be used to measure immunogenicity of the vaccine preparation Participants will be involved in study related procedures for up to 8 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None